NRSN Stock Forecast & Price Target

NeuroSense Therapeutics is attractive because PrimeC has shown a differentiated multi-target mechanism that addresses several shared drivers of neurodegeneration—neuroinflammation, autophagy dysfunction, miRNA dysregulation, and iron imbalance—rather than relying on a single-pathway approach. Its ALS program is the strongest near-term value driver, with Phase 2b PARADIGM showing favorable safety, significant reductions in TDP-43, a 36.3-month median survival versus 21.4 months after crossover, and a 65% lower risk of death, while the company also has FDA-cleared Phase 3 PARAGON and a potential Canada filing in late 4Q26. The bull case is further reinforced by early Alzheimer’s biomarker signals, preclinical Parkinson’s work, and an NPV-based valuation that assigns 68% of value to ALS and 32% to AD, though financing needs and dilution risk remain important constraints.

NeuroSense Therapeutics is a clinical-stage biotech with no approved products, so its value depends almost entirely on PrimeC, a high-risk combination therapy that has yet to prove efficacy or regulatory viability across ALS, Alzheimer’s disease, or Parkinson’s disease. Its financial profile is fragile, with only $0.17 million in cash at the end of 2025, a 20% discount rate already applied for elevated financing and dilution risk, and a real possibility of additional equity raises. The bearish view is further reinforced by clinical, regulatory, and commercial uncertainty, plus two Nasdaq deficiencies with a September 29, 2026 cure deadline that could impair access to capital and threaten the planned pivotal ALS trial.